Previous studies showed that methylprednisolone (MePDN) down-regulates the surface expression of activating NK receptors and sharply inhibits the NK cytotoxicity both in vitro and in vivo. Since MePDN is administered to patients undergoing hemopoietic stem cell transplant to treat acute graft versus host disease (GvHD), we analyzed whether it could also inhibit the NK cell differentiation from CD34 1 hemopoietic cell precursors, thus interfering with the development of effector cells with antileukemic potential. We show that MePDN promotes the in vitro differentiation of CD161 1 CD56
Introduction
NK cells play a critical role in the host defenses because of their capability of mediating cytolytic activity and releasing cytokines in the course of immune responses against viruses and tumor cells (1) (2) (3) . NK cell function is regulated by a balance between activating and inhibitory signals (3) (4) (5) (6) (7) . Upon specific recognition of HLA-class I molecules, the HLA-class I-specific inhibitory receptors [killer Ig-like receptors (KIRs)] suppress the NK cell-mediated cytolytic activity. Accordingly, NK cell activation and target cell lysis requires a partial or complete down-regulation of HLA-class I molecules on target cells (2) (3) (4) (5) . However, NK cell activation also requires the interaction between activating NK receptors expressed at the NK cell surface and specific ligands expressed on target cells (6) (7) (8) . Activating NK receptors include NKp46, NKp30 and NKp44, collectively referred to as 'natural cytotoxicity receptors' (NCRs), NKG2D and DNAM-1 (6) (7) (8) (9) (10) (11) (12) . NKp46, NKp30, NKG2D and DNAM-1 are present on both resting and activated NK cells, while NKp44 is expressed only upon NK cell activation. Other receptors including 2B4, NTBA and NKp80 function primarily as co-receptors as they can significantly increase the NK cell cytotoxicity when coengaged with NCR or NKG2D (13) (14) (15) (16) .
A number of in vitro studies analyzing the human NK cell differentiation from CD34 + hemopoietic stem cell (HSC) precursors suggested that the appearance of fully competent NK cells is associated with a non-random, sequential acquisition of NK cell receptors and functions. CD161, NKp46, NKp44 and 2B4 are the first NK cell receptors to be expressed at the cell surface. Subsequently, NK cells undergoing maturation express CD94/NKG2A, as the first HLAclass I-specific inhibitory receptor, while CD16 and KIRs appear at later stages. Collectively, these data suggested that human NK cells undergo differentiation through discrete stages of development (17) (18) (19) (20) (21) (22) .
Data regarding human NK cell differentiation in vivo have been reported in studies performed on cells recovered either from PB or from bone marrow of patients undergoing hemopoietic stem cell transplantation (HSCT). Although some degree of similarity exists between in vitro and in vivo data, a delay in NK cell differentiation and some perturbations in the NK cell repertoire have been observed in vivo, at least in some patients (23) (24) (25) (26) . Remarkably, in recent years, NK cells have been shown to play a central role in the positive clinical outcome in patients undergoing allogeneic HSCT to treat acute myeloid leukemias (27) (28) (29) . This is particularly true in the case of haploidentical HSCT carrying KIR-HLA-class I mismatches in the donor's recipient direction. In this transplantation setting, the activity of NK cells is related not only to their graft-anti-leukemia effect but also to their ability to prevent graft versus host disease (GvHD), graft rejection and, at least in part, to provide a first line of defense against lethal viral infections (27-32). These positive effects are mediated by mature NCR + KIR + NK cells that are mismatched with the patient's HLA-class I alleles (30) (31) (32) (33) . Therefore, it is crucial to better define the various stages of NK cell differentiation from HSC to mature KIR + NK cells. In addition, since patients undergoing HSCT may be treated with immunosuppressive drugs, it is particularly relevant to analyze the effect of these drugs both in mature NK cells and in NK cells undergoing differentiation. In this context, we have previously shown that NK cells, isolated from PB of pediatric patients receiving allogeneic HSCT who had been treated with methylprednisolone (MePDN) to control GvHD, displayed a sharp down-regulation of the surface expression of NCR and of their lytic activity. In addition, a similar impairment of NK cell function was detected in PB NK cells isolated from healthy donors that had been cultured in vitro in the presence of IL-2 and MePDN (34) . We have also shown that the MePDN-induced inhibitory effect correlates with the inhibition of Tyr-phosphorylation of Signal Transducer and Activator of Transcription (STAT) 1, 3, 5 and of Extracellular Signal-Regulated Kynase (ERK) 1/2 as well as with a deficient granule exocytosis (35) .
In this context, recent studies have analyzed the in vitro effect of hydrocortisone (HC) both on mature NK cells and on NK cell precursors undergoing in vitro differentiation. It is of note, however, that different from our previous study using pharmacological concentrations of MePDN. Physiological concentration of HC enhanced proliferation and cytolytic activity of mature NK cells and also exerted a positive effect on NK cell differentiation in vitro (36, 37) . It should be noted that MePDN and HC are commonly used in different clinical situations and display different biological activities. Since MePDN is routinely used in the treatment of GvHD, in patients undergoing HSCT, it is particularly relevant to define its possible effects also on NK cells undergoing maturation from CD34 + HSC. In the present study, we analyzed the NK cell differentiation from CD34 + isolated from human umbilical cord blood (UCB) and cultured in an appropriate medium in the presence or in the absence of MePDN. We show that MePDN promotes an accelerated NK cell differentiation and induces myeloid CD33 + CD161 À cell precursors to switch towards CD33 dull CD161 + immature NK cells. Importantly, NK cells undergoing differentiation in the presence of MePDN acquired an efficient cytolytic activity, but failed to produce significant amounts of cytokines.
Methods

Isolation of CD34
+ from UCB and cell culture 
Cytolytic assay
NK cell cytotoxicity was analyzed in a 4-h 51 Cr-release assay against the melanoma FO1 (MFO1) human cell line and the FccR + P815 mastocytoma murine cell line as previously described (40) . All experiments were performed in duplicates; data are expressed as percentage of lysis of target cells. The E/T ratio was 5:1 and it was calculated on the percentages of NK cells present in each culture. To this end, we performed cytofluorimetric analysis on culture supernatants collected at different time intervals using the Flow Cytomix kit TH1/TH2 and Flow Cytomix kit IL-13 immunoassays (Bender MedSystem, Vienna, Austria) according to the manufacturer's instructions. The principle of the immunoassay is based on the presence of fluorescent microbeads coated with mAbs specific for each cytokine to be detected in the system. The beads can be differentiated by their sizes and by their distinct spectral addresses. Briefly, a mixture of coated beads is incubated with samples or standard mixture and then a biotin-conjugated second antibody mixture is added. The presence of biotin conjugates is further revealed by a streptavidin-PE reagent. Samples have been processed on FACS Calibur and data have been analyzed by BenderMed System Flow Cytomix Software (Bender MedSystem).
Analysis of cytokine release
In some experiments, cells were harvested, washed and then plated in a 96 U-bottom plate (Falcon and Becton Dickinson) at 1 3 10 5 per well and were cultured overnight in medium alone (i.e. without cytokines) or were stimulated with a mixture of phorbol myristate acetate (PMA) (50 ng ml À1 ) and ionomycin (25 ng ml The majority of these G2-gated cells were CD117 + while CD56 was expressed in variable percentages (Fig. 1, panel A) .
Further analysis of the expression of NK receptors on CD161 + cells revealed a surface phenotype (CD161
) typical of immature NK cells (Fig. 1, panel C, empty profiles) . This surface phenotype would correspond to the stage three/four of NK cell differentiation as proposed by Caligiuri et al. (21, 22) . Only a small fraction of these NK cells were LFA-1 + (Fig. 1 , panel C, empty profiles) while this adhesion molecule was mostly confined to the CD33 + myelomonocytic cell population (data not shown). In agreement with previous studies (22) , the only HLA-class I-specific inhibitory receptor detectable at this stage of NK cell differentiation in a minority of CD161 + CD56 + cells was represented by NKG2A ( Fig. 1 , panel C, empty profiles).
The parallel analysis of cell precursors cultured in the presence of MePDN revealed remarkable differences with respect to control cell cultures. Thus, the G1-gated CD33 + myelomonocytic cell population was sharply decreased (Fig. 1, panel B , upper dot plot, gate G1 and gray histogram), while the majority of the other (G2 gated) CD161
+ cell population expressed CD56 at the cell surface (Fig. 1, MePDN accelerates NK precursors differentiation, hemopoietic stem cells 567 was dose dependent: at concentration of 10 À8 M, the phenotype of cells recovered was undistinguishable from that of cultures performed in the absence of MePDN (data not shown). It is important to note that, at day 25 of culture, the total number of cells recovered was similar under the different culture conditions (Fig. 2, panel A) . However, a major difference existed in the proportion of NK cells that was consistently much higher in the presence of MePDN (Fig. 2,  panel B) .
Taken together, these data suggest that MePDN may induce a preferential and accelerated differentiation of CD34 + HSC toward the NK cell lineage.
NK cells undergoing in vitro differentiation in the presence of MePDN display an efficient cytolytic activity
We have previously shown that, in mature NK cells, MePDN induces a sharp inhibition of natural cytotoxicity (34, 35) . Thus, we analyzed whether a similar effect was exerted also in NK cells undergoing in vitro differentiation from CD34
+ hemopoietic cell precursors. To this end, hemopoietic cell precursors, that had been cultured for 25 days in the absence or in the presence of MePDN, were tested for their ability to kill the NK-susceptible, HLA-class I À MFO1 cell line. In agreement with previous data, the cytolytic activity of cells cultured under standard conditions (in the absence of steroid) was low (Fig. 3, panel A, black bar) . On the other hand, as shown in Fig. 3, panel A, Since cells cultured in the presence of MePDN expressed higher amounts of activating NK receptors as compared with the controls, we further analyzed the NK receptor-mediated cytotoxicity in a redirected killing assay using the FccR + P815 cell line as target cells. Figure 3, These data further indicate that NK cytotoxicity is not impaired by MePDN but, instead, it is significantly enhanced, likely reflecting the higher proportion of NK cells and the higher surface density of activating NK receptors. It is also noteworthy that cells cultured either in the absence or in the presence of MePDN expressed 2B4 molecules characterized by an inhibitory activity (both in spontaneous and in NKp46-induced cytotoxicity). This is in agreement with previous data indicating that, in immature NK cells, 2B4 functions as an inhibitory receptor (18) .
Cytokine release from immature NK cells undergoing in vitro differentiation in the absence or in the presence of MePDN During the past several years, attempts have been made to characterize the pattern of cytokines produced by NK cells at different stages of differentiation. It has been reported that CD161 + CD56 +/À immature NK cells release, upon stimulation with IL-2 or PMA + ionomycin, IL-13 and TNF-a or granulocyte macrophage colony-stimulating factor (GM-CSF), respectively. In contrast, IFN-c production was detectable only at later stages of NK cell differentiation, following appropriate stimuli (e.g. IL-12 and IL-18) (21, 22, 42, 43) . In this context, we analyzed the production of cytokines in cells cultured as indicated above, either in the presence or in the absence of MePDN. Supernatants were collected at day 25 of culture: samples were tested for a large panel of cytokines by an immunocytofluorimetric assay (see Methods). in the absence of MePDN (black bars), cells produced high levels of IL-8, while IL-13 was present in lower concentrations. Low amounts of IL-12, IL-10 and IL-6 could also be detected while TNF-a/-b release was not detected with the exception of few experiments (see Fig. 4 , panel B and Fig. 7 ). On the other hand, in cells cultured in the presence of MePDN, the levels of IL-8 and IL-13 were low (gray bars). Remarkably, stimulation of the same cell populations with a PMA + ionomycin mixture (in the absence of any cytokine) confirmed that these cells produced relevant amounts of IL-8 only. Figure 4, The fact that they belong to the NK cell lineage was further supported by the expression of NKp44, an NK-specific activating receptor.
CD161
+ CD56 + LFA-1 À immature NK cells produce large amounts of IL-8
A remarkable finding was the high production of IL-8 in CD34
+ cells that had been cultured in the absence of MePDN (see Fig. 4, panel A) . Since these cell populations contained large proportions of myelomonocytic cells, it was important to analyze which cell population was responsible for the production of IL-8. To this end, we analyzed the three cell populations defined above and purified by cell sorting namely, CD161 cell populations were further cultured in the presence of SCF, FLT3-L, IL-7, IL-15 and IL-21 (in the absence of MePDN). The presence of secreted cytokines was evaluated by an immunocytofluorimetric assay (see Methods). Figure 7 shows a representative experiment (out of three). As previously shown in unfractioned cells, cells produced high amounts of IL-8 and low amounts of IL-13 and TNF-a. Importantly, in addition to IL-13 and TNF-a, CD161
+ CD56 + LFA-1 À cells also produced IL-8, thus supporting the notion that immature NK cells may indeed produce this important chemokine.
Discussion
In this paper, we show that pharmacological concentrations of MePDN can induce a preferential and accelerated differentiation of CD34 + hemopoietic precursors toward NK cells. In the presence of MePDN, cultured cells expressed high proportions of activating NK receptors and efficient cytolytic activity. Importantly, MePDN was capable of inducing cells with the characteristic of myeloid precursors to switch toward immature NK cells. It is also of note that immature NK cells cultured in the absence of MePDN produced high amounts of IL-8. In a previous report, we showed that MePDN administration in pediatric patients undergoing HSCT resulted in down-regulation of both NCR expression and NK cytotoxicity in mature PB NK cells. A similar inhibitory effect was also observed in vitro in IL-2-induced NK cells derived from healthy donors that had been cultured in the presence of MePDN at a final concentration of 10 À6 M (34). In particular, MePDN was found to inhibit cell proliferation, to induce an increase of apoptotic cell death, to down-regulate the surface expression of NKp30 and NKp44 and to impair the NK cell cytotoxicity (34, 35) . These effects were found to be consequent to the inhibitory effect on the Tyr-phosphorylation of STAT 1, 3, 5 and ERK 1/2 molecules and on the granule exocytosis (35) . Since MePDN is commonly administered to HSC-transplanted patients to treat acute GvHD, it was important to analyze whether it could also affect NK cell differentiation. This notion is relevant since NK cells have been shown to exert a potent anti-leukemic activity at least in the haploidentical transplantation setting (in the presence of KIR/HLA-class I mismatches). To this end, CD34
+ cell precursors were cultured in media supplemented with appropriate cytokines in the absence or in the presence of MePDN and analyzed after 3-4 weeks of culture. Remarkably, in the presence of MePDN, there was a net enrichment of the cell fraction with phenotypic characteristics of NK cell precursors while the CD56 ), while those cultured in the presence of MePDN expressed activating NK receptors including NKp46, NKG2D and DNAM-1 and the inhibitory receptor NKG2A, suggesting the acquisition of a more mature phenotype (18, 19, 22) during the same time interval of culture. Analysis of the NK cell cytolytic activity confirmed that CD161 + CD56 + cells, developed in the presence of MePDN, were functionally active. This correlated with the surface expression of the major activating NK receptors (NKp46 and NKG2D) and of adhesion molecules (LFA-1) crucial for an efficient target cell lysis.
Other studies analyzed the in vitro effect of HC both on mature NK cells and on NK cell precursors undergoing in vitro differentiation (36, 37, 44) . Different from our previous results using MePDN, physiological concentrations of HC were found to enhance cell proliferation and cytolytic activity of mature NK cells (36) . On the other hand, two of these studies are in agreement with our present data showing accelerated NK cell differentiation from CD34 + UCB precursors (37, 44) . It is possible that discordant results regarding the effect on mature PB-derived NK cells may reflect the use of different steroids which display different biological activities or be due to differences in the experimental setting. Importantly, in our previous studies, MePDN exerted its inhibitory effect on mature PB NK cells at the pharmacological concentration of 10 À6 M (35), i.e. the same concentration which exerts a positive effect on NK cell precursors. On the contrary, HC was used at the physiological concentrations of 10 À6 M (35) (36) (37) 44) . Moreover, in our present study, cultures containing MePDN used at lower concentrations (10 À7 M or 10 À8 M) did not differ from control cultures without MePDN (data not shown).
During the past years, various attempts have been made to define the pattern of cytokines produced by NK cells at different stages of differentiation. It has been reported that CD161 + CD56 +/À immature NK cells are capable of producing IL-13, TNF-a and GM-CSF upon stimulation with IL-2 or PMA-ionomycin, respectively. Production of IFN-c only occurs at later stages of NK cell differentiation (22, 37, (42) (43) (44) . In our experimental setting, cells derived from CD34 + cord blood precursors in the absence of MePDN secreted high amounts of IL-8, while IL-13 was produced in lower but significant amounts. Remarkably, MePDN appeared to selectively prevent IL-8 and IL-13 release. However, since control cultures included both immature myeloid and immature NK cells, it was not possible to define which cell population was actually responsible for the IL-8 production. 
CD56
À LFA-1 + myeloid cell precursors were further cultured in the presence or in the absence of MePDN. Only in the presence of MePDN, cells could acquire the CD33 low CD161 + CD56 + surface phenotype. In this context, different studies have recently reported the existence of common lymphoid-myeloid progenitors which can give rise either to myeloid or to lymphoid cells (44, 47, 48) .
In conclusion, our present study provides evidence for a dichotomous effect of MePDN on immature versus mature NK cells. In addition, it shows a preferential positive effect on NK cell maturation, while exerting an inhibitory effect on the myeloid compartment. This effect should be taken into account and further investigated in HSCT patients receiving steroids to treat GvHD.
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Supplementary Figure 3 is available at International Immunology Online.
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